ROS1, ALK, and NTRK Fusions in Head and Neck Cancers
Head and neck cancers arise from areas of soft, moist skin called mucous membranes. Papillary thyroid cancer and cancers of the salivary glands have the most evidence for gene fusions in NTRK genes.
- An estimated 5% to 13% of Papillary Thyroid Cancers contain NTRK1 gene fusions, while an additional 2% to 14% are thought to carry NTRK2 gene fusions.
- About 3% of all salivary gland tumors contain rearrangements of the NTRK3 gene.
- In 2010, researchers discovered MASC (mammary analog secretory carcinoma), a rare subtype of salivary gland cancer that harbors NTRK3 gene fusions in 90%-100% of cases.
- A percentage of patients with brain cancers, such as astrocytoma and glioblastoma, have also tested positive for these genetic changes.
These statistics mean that a significant proportion of affected individuals have a genetic profile that may make their cancer a candidate for the STARTRK-2 clinical trial.
See if you or a loved one may be eligible for the study.
Detecting actionable gene rearrangements is crucial to finding the best targeted treatment strategy for a patient. Our Central Diagnostic Lab uses state-of-the-art molecular and genetic testing to deliver conclusive results in about two weeks.